Morgan Stanley Delcath Systems, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Morgan Stanley holds 106,476 shares of DCTH stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
106,476
Previous 103,133
3.24%
Holding current value
$1.03 Million
Previous $863,000
11.36%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding DCTH
# of Institutions
73Shares Held
7.62MCall Options Held
198KPut Options Held
41.7K-
Aigh Capital Management LLC Baltimore, MD1.78MShares$17.3 Million6.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.11MShares$10.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA997KShares$9.66 Million1.32% of portfolio
-
Essex Investment Management CO LLC Boston, MA337KShares$3.26 Million0.57% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny312KShares$3.02 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $83.3M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...